Ftse Mib
35.171,11
1,02%
DAX
18.716,42
-0,12%
S&P 500
5.246,68
0,48%
NASDAQ
16.511,18
0,75%
Bitcoin
61.645,03
-2,00%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ CRISPR Therapeutics AG (CRSP) CRISPR Therapeutics AG (CRSP) Notizie

CRISPR Therapeutics AG

CRSP
55,50
-0,15 (-0,27%)
Dopo l'orario di negoziazione
Ultimo aggiornamento: 23:25:10
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
09/5/202414:30GLOBECRISPR Therapeutics to Present at the Bank of America..
08/5/202422:20EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/5/202422:00GLOBECRISPR Therapeutics Provides Business Update and Reports..
08/5/202413:00GLOBECRISPR Therapeutics Highlights ASGCT Oral Presentation and..
22/4/202422:30GLOBECRISPR Therapeutics to Present Oral Presentation at the..
03/4/202414:00GLOBECRISPR Therapeutics to Present at the Annual Needham Virtual..
01/4/202414:00GLOBECRISPR Therapeutics to Present at the American Society of..
13/3/202413:30GLOBECRISPR Therapeutics Proposes New Appointment to the Board of..
21/2/202423:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/2/202423:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/2/202413:50EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
21/2/202413:45EDGAR2Form 8-K - Current report
21/2/202413:30GLOBECRISPR Therapeutics Provides Business Update and Reports..
16/2/202423:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/2/202422:30EDGAR2Form 144 - Report of proposed sale of securities
15/2/202414:30GLOBECRISPR Therapeutics to Present at the Citi 2024 Virtual..
13/2/202414:44EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
13/2/202414:30GLOBECRISPR Therapeutics Announces $280 Million Registered Direct..
13/2/202412:30EDGAR2Form 8-K - Current report
13/2/202408:30GLOBEEuropean Commission Approves First CRISPR/Cas9 Gene-Edited..
31/1/202423:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/1/202422:08EDGAR2Form 144 - Report of proposed sale of securities
29/1/202422:00EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
18/1/202423:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/1/202423:00EDGAR2Form 144 - Report of proposed sale of securities
16/1/202422:11EDGAR2Form 8-K - Current report
16/1/202422:01GLOBECRISPR Therapeutics Announces U.S. Food and Drug..
10/1/202417:36EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
08/1/202413:00GLOBECRISPR Therapeutics Highlights Strategic Priorities and 2024..
03/1/202414:30GLOBECRISPR Therapeutics to Present at the 42nd Annual J.P...
19/12/202322:23EDGAR2Form 8-K - Current report
15/12/202314:58EDGAR2Form 8-K - Current report
13/12/202315:22EDGAR2Form 8-K - Current report
08/12/202322:11DJNBluebird Bio Shares Slide 41% on Black-Box Label, Higher..
08/12/202319:16EDGAR2Form 8-K - Current report
08/12/202318:52BWVertex and CRISPR Therapeutics Announce US FDA Approval of..
08/12/202317:46DJNCRISPR, Vertex Get FDA OK of Casgevy Gene Therapy in..
04/12/202322:26EDGAR2Form 8-K - Current report
04/12/202322:15GLOBECRISPR Therapeutics Announces Updates to Immuno-Oncology..
16/11/202313:21EDGAR2Form 8-K - Current report
16/11/202307:45BW Vertex and CRISPR Therapeutics Announce Authorization of..
06/11/202322:42EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
06/11/202322:33EDGAR2Form 8-K - Current report
06/11/202322:15GLOBECRISPR Therapeutics Provides Business Update and Reports..
06/11/202311:01GLOBECRISPR Therapeutics Announces Preclinical Data at the..
01/11/202311:29DJNCrispr Therapeutics Shares Rally Premarket After Favorable..
31/10/202322:53GLOBECRISPR Therapeutics Announces Completion of FDA Advisory..
31/10/202312:05GLOBECRISPR Therapeutics Trading Halted Today; FDA Advisory..
17/10/202323:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/10/202323:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
Apertura: 56,84 Min: 55,40 Max: 59,1774
Chiusura: 55,65

La tua Cronologia

NASDAQ
CRSP
CRISPR Therapeutics
LSE
0DEF
Alfio Bardolla Training
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network